RBC Capital maintains Outperform on Rhythm Pharmaceuticals
RBC Capital maintained its Outperform rating on Rhythm Pharmaceuticals and raised its price target to $159 from $155.
Story updates
03:07:15 PM UTC
SquawkNews
Rhythm Pharmaceuticals Is Maintained at Outperform by RBC Capital
03:07:29 PM UTC
SquawkNews
Rhythm Pharmaceuticals Price Target Raised to $159.00/Share From $155.00 by RBC Capital